Our 2017 Cancer Immunotherapy 2.0 report featured in Drug Development & Delivery

Like
Allan B. Haberman, Ph.D

 

Drug Development and Delivery published an article based on our 2017 report on Cancer Immunotherapy 2.0 in its November/December 2017 issue.

To see the article, please go to http://www.drug-dev.com/Main/Back-Issues/CANCER-IMMUNOTHERAPY-Building-on-Initial-Successes-1402.aspx

To order our report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes, please see the CHI Insight Pharma Reports website.
______________________________________________________________________________________________________________________________________________

As the producers of this blog, and as consultants to the biotechnology and pharmaceutical industry, Haberman Associates would like to hear from you. If you are in a biotech or pharmaceutical company, and would like a 15-20-minute, no-obligation telephone discussion of issues raised by this or other blog articles, or of other issues that are important to your company, please contact us by phone or e-mail. We also welcome your comments on this or any other article on this blog.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment